酪氨酸蛋白激酶EphA7蛋白在非小细胞肺癌组织中的表达  

Expression of Tyrosine Kinase EphA7 in the Non-small Cell Lung Carcinoma

作　　者：孟祥瑞[1] 陆鹏[1] 刘桂举 肖鹏[1] 白桦[1] 栗敏[1] 李瑞君[1] 梅家转[1] 

机构地区：[1]郑州人民医院肿瘤内科,河南郑州450003

出　　处：《肿瘤基础与临床》2014年第3期193-196,共4页journal of basic and clinical oncology

摘　　要：目的探索非小细胞肺癌(NSCLC)组织中EphA7蛋白的表达及其临床意义。方法采用免疫组化法检测66例手术切除的NSCLC组织中EphA7蛋白表达情况,并探索其与临床病理特征的关系。结果全组66例患者中,EphA7蛋白表达阳性率56.06%。EphA7蛋白的表达与纤维化和肿瘤大小有关(P<0.05)。EphA7的表达与肿瘤增殖能力有关(P<0.05)。单因素生存分析及多因素生存分析结果显示增强EphA7表达已确定为有利的患者生存预测因素(P<0.05)。结论 EpA7可能参与NSCLC发展过程,可作为临床肿瘤标志物,并可用作将来治疗的靶点。Objective To evaluate the clinical significance of EphA7 protein expression in non-small cell lung carcinoma（NSCLC）. Methods EphA7 protein expression was assessed by using immunohistochemically in the 66 surgically resected NSCLC and was analyzed in the relation with clinicopathological characteristics. Results The positive rate EphA7 protein was 56.06% in the NSCLC. EphA7 protein expression was significantly associated with, fibrosis and tumor size（P 〈 0.05）. EphA7 expression was positively associated with tumor proliferative capacity（ P 〈 0.05 ）. EphA7 expression were identified as predictors of favourable patients＇ survival at both univariate and mul- tivariate levels （ P 〈 0.05 ）. Conclusion EphA7 may be involved in progression of NSCLC, reinforcing their utility as clinical bion,arkers for patient＇ s management and prognosis, as also as potential targets for future therapeutic in- terventions.

关 键 词：EphA7蛋白 非小细胞肺癌 免疫组化 

分 类 号：R734.2[医药卫生—肿瘤] R730.23[医药卫生—临床医学]